Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017
August 15, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
The Company has Generated Revenues and Advanced in R&D for Intranasal Ampligen and in Immuno-Oncology Conference Call Scheduled for Tuesday, August 15th at 1:00 PM EDT PHILADELPHIA, Aug. 15,...
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated
August 14, 2017 08:30 ET
|
LinkedIn
PHILADELPHIA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist®...
Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017
August 11, 2017 10:20 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2017 second quarter financial...
Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
August 08, 2017 06:08 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian...
Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome
August 04, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may provide the basis for a...
Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer
July 10, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 10, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen...
Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
May 31, 2017 12:03 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to bolster its scientific capabilities by...
Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities
May 31, 2017 11:38 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
May 15, 2017 17:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately...
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016
March 31, 2017 18:19 ET
|
Hemispherx Biopharma, Inc.
Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value Conference Call...